Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label safety study of aducanumab in prior aducanumab feeder-study participants with Alzheimer's disease
NL-OMON52801Phase 3Completed
- Sponsor
- IQVIA
- Start
- Jan 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of aducanumab in Alzheimer's disease (AD) (2 arms), sponsored by IQVIA. Primary endpoint: Incidence of adverse events, serious adverse events, ARIA, and immunogenicity over 100 weeks. Started Jan 2021; status: completed.
02
Drugs
aducanumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON52801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52801.